Tom Gardner's 2026 Outlook: Volatility, Government Scrutiny, and Two AI-Adjacent Stocks

Motley Fool CEO Tom Gardner counsels investors to prepare for sudden drawdowns—citing the Nasdaq's 2000 peak-to-trough 78% collapse—and recommends diversification (minimum ~25 stocks, 5+ year horizon, and a 40% single-position risk check). Gardner argues today's AI-led cycle differs from the dot-com era (more profitable business models and fewer IPOs), predicts increased government intervention and energy/cost pressures on large tech over the next 12 months, and identifies EMCOR (EME) as a data-center infrastructure beneficiary and Moderna (MRNA) as an AI-accelerated drug-discovery beneficiary; Motley Fool discloses positions in both names.

Analysis

Market structure: Regulation-driven cost allocation to large tech shifts near-term economic winners to service providers and infrastructure owners. Data-center contractors (EME), power utilities and select industrials should see demand for installation/maintenance grow while hyperscalers face margin pressure; expect mid-single-digit to low-double-digit revenue tailwinds for contractors in 12–24 months and regional power-price spikes of ~5–10% where new capacity is constrained.

Risk assessment: Tail risks include aggressive antitrust/energy levies within 6–12 months compressing big-tech operating margins by 5–20%, an AI overpromise in drug discovery producing biotech trial failures (>30% drawdowns), or a data-center capex oversupply causing pricing corrections of 20–40%. Hidden dependency: EMCOR’s backlog is materially correlated to hyperscaler capex — if cloud spend pauses, contractor revenues lag by one quarter; key catalysts are Congressional/FTC actions, DOE energy reports, NVDA earnings, EMCOR backlog releases, and Moderna clinical/data milestones.

Trade implications: Construct asymmetric exposure — favor mid-cap infrastructure (EME) and selected biotech (MRNA) while hedging tech concentration. Use position sizing (2–3% EME, 1–2% MRNA) with defined stops, buy 3–6 month put spreads on NVDA/MSFT as portfolio insurance, and trim 3–5% of cap-weighted index exposure into industrials/healthcare over the next 30–90 days ahead of potential regulatory moves.

Contrarian angles: Consensus undervalues that regulation can accelerate outsourcing and onshoring, benefiting contractors, utilities and data-center REITs (e.g., EQIX) more than it damages the whole AI stack. Conversely, shorting NVDA/MSFT is asymmetric — their strategic bargaining power and indispensable silicon mean regulatory news may be priced in; watch backlog, capex cadence and Model/clinical readouts for mispricings over 3–12 months.

Key Decisions for Investors

• Establish a 2–3% long position in EMCOR (EME) within 30 days as a 12–24 month infrastructure play; target +30–60% upside, set a tactical stop-loss at -25% and reassess if quarterly backlog growth is <5% y/y or if major hyperscalers cut build plans.
• Initiate a 1–2% long position in Moderna (MRNA) as a 24-month asymmetric biotech/AI-exposure bet; trim 50% on a +50% move, cut at -35% if trial readouts or guidance materially disappoint (>15% revenue guide miss), and add on confirmed AI-drug-discovery partnership announcements.
• Reduce cap-weighted S&P/QQQ exposure by 3–5% over the next 60 days and redeploy into industrials/healthcare (EME, MRNA, data-center REITs such as EQIX) to lower concentration risk and capture infrastructure rerating if regulation hits big tech.
• Buy 3–6 month put spreads as insurance against an AI/regulatory shock: e.g., NVDA 3–6 month 10% OTM put / 20% OTM put sold to cap cost (target net debit <2% of protected portfolio slice), and/or use protective collars (buy 5–10% OTM puts, sell near-term calls) on core large-tech holdings during the next earnings window.